In 2009, castration-resistant metastatic prostate cancer continues to account for more deaths in US men than any other cancer apart from lung cancer. Although novel targeted molecular, hormonal and immunologic agents are accelerating in their development in this disease, docetaxel and prednisone remain the standard palliative regimen for the majority of men who have progressed despite hormonal therapies. Thus, understanding the practical and often subtle issues of docetaxel initiation, duration of therapy, cessation of therapy and treatment holidays is critical for the informed use of this US Food and Drug Administration-approved regimen. In this review we address these topics in light of prognostic and predictive factors to help guide the rational use of docetaxel chemotherapy in men with this aggressive disease.
Introduction
Prostate cancer is the most commonly diagnosed nonskin cancer in adult males in the USA. 1 The American Cancer Society estimated that during 2009 about 192 280 new cases of prostate cancer would be diagnosed in the USA, along with 27 360 deaths from prostate cancer. 2 In Europe, around 300 000 new cases of prostate cancer are diagnosed annually. 3 Metastatic prostate cancer is initially treated with androgen-deprivation therapy (ADT); although the disease initially responds well to ADT, progression occurs in the majority of patients, leading to castration-resistant prostate cancer (CRPC). Men with CRPC may experience symptomatic progression, resulting in weight loss, fatigue or pain from bone metastases, all of which can negatively impact quality of life (QoL). Two landmark trials (TAX 327 and Southwest Oncology Group (SWOG) 9916) 4, 5 showed superior survival and pain palliation with the use of docetaxel-based regimens compared with mitoxantrone/prednisone. Based on these findings, docetaxel combined with low-dose prednisone was approved by the US Food and Drug Administration for first-line chemotherapy in men with metastatic androgen-independent prostate cancer. Currently, no agent has been approved for second-line therapy following progression after docetaxel and prednisone, although a number of novel agents and other chemotherapeutics are under investigation.
The decision of when to initiate docetaxel-based chemotherapy is an important one that is not clearly addressed by existing treatment guidelines. A number of prognostic nomograms have been devised that assess multiple disease variables and aid in decisions about the timing and type of treatment to be given. However, it is widely acknowledged that there is a need for closer multidisciplinary collaboration between urologists, medical oncologists and radiation oncologists to optimize patient management.
This review addresses the factors that contribute to treatment decisions and offers guidance for the rational treatment of men with CRPC.
Indications for chemotherapy
The majority of men with prostate cancer are diagnosed with localized disease, with only 4-6% of men diagnosed with metastatic disease. 2 Following local therapy (surgery and/or radiation), the disease subsequently recurs in about 30% of men in the form of biochemical relapse or a rise in serum levels of PSA. 6 Observation, ADT, local salvage treatments (if indicated) or clinical trials are used in this situation to prevent or delay the development of metastatic disease. At this stage, treatment is dictated by the 'pace' of the disease (PSA doubling time, PSA velocity), burden of disease (metastatic or symptomatic disease) and previous local treatments. Most patients whose serum PSA level continues to rise will subsequently receive some form of ADT, typically a gonadotropin-releasing hormone agonist, which results in suppression of serum testosterone production in the testes and a subsequent drop in serum PSA levels. However, most patients will develop evidence of resistance to ADT owing to the development of a subpopulation of prostate epithelial cells that can survive independently of testicular androgen deprivation. At this point, the disease is termed CRPC.
Following a period of time on ADT, castration-resistant growth may occur, often initially manifested by a solitary PSA rise in the face of castrate levels of testosterone. The time to metastatic disease in this population depends on the baseline serum PSA level and PSA doubling time 7 ; therefore, this patient group should be monitored closely. Historically referred to as androgen-independent prostate cancer, this disease state may remain sensitive to low levels of androgen, and hence, some patients may respond to further hormonal manipulations. In CRPC, the androgen receptor can remain active, therefore secondary hormone therapies, including antiandrogens (for example, bicalutamide, flutamide or nilutamide) or inhibitors of steroidal hormone production (for example, ketoconazole) can be considered as options for disease control. 8 Although no secondary hormonal therapy has shown a prolongation of survival, PSA decreases of X50% have been reported in 20-80% of patients, with a typical response duration of 2-6 months. 9 Patients with CRPC typically fail one or more secondary hormonal manipulations before chemotherapy, depending on the pace of the disease. Docetaxel and prednisone chemotherapy has shown significant clinical benefit in this patient population and is considered the standard of care for metastatic CRPC.
Clinical benefit associated with docetaxel-based chemotherapy
The TAX 327 study showed a prolongation of overall survival (OS) compared with mitoxantrone and prednisone, as well as improved palliation of disease-related symptoms compared with prednisone alone. 4, 10 These findings led to the US Food and Drug Administration and European regulatory approval of docetaxel and prednisone for the treatment of men with metastatic CRPC. 11, 12 Docetaxel is also the recommended first-line chemotherapy for CRPC according to the National Comprehensive Cancer Network prostate cancer guidelines. 8 The SWOG 9916 study compared docetaxel and estramustine against mitoxantrone and prednisone. Median survival and PSA decline of X50% were significantly improved in the docetaxel arm (Table 1) . The median time to disease progression was 6.3 months with docetaxel and estramustine compared to 3.2 months with mitoxantrone and prednisone (Po0.001). 5 Patients treated with docetaxel and estramustine experienced improved objective responses compared with those treated with mitoxantrone and prednisone (17 versus 11%); however, grade III/IV neutropenic fever, nausea and vomiting, and cardiovascular events were more common in the docetaxel/estramustine arm. 5 Outcomes in the TAX 327 study confirmed the superiority of docetaxel and prednisone chemotherapy to mitoxantrone and prednisone. The initially reported OS benefit for docetaxel and prednisone-treated patients of 2.4 months at a median follow-up of 20.8 months 4 increased to 2.9 months in an updated survival analysis after a further 3.5-year follow-up ( Figure 1) . 13 Furthermore, patients treated with 3-weekly docetaxel and prednisone doses experienced improved pain palliation (35 versus 13 Optimizing docetaxel in metastatic CRPC AJ Armstrong and DJ George adverse event rate with a range of mild to moderate toxicities for 3-weekly docetaxel and prednisone doses. 4 One common misinterpretation of the clinical results from these Phase III studies is that if 10 cycles (7 months) of docetaxel-based chemotherapy only improve survival by 3 months, then the toxicity of treatment is not worth the benefit. Neither of these studies compared docetaxelbased regimens against a placebo control. Although subject to some bias, a more practical assessment might be to consider the potential benefit of therapy among the majority of men who achieve a response.
Prostate-specific antigen has been used both as a biomarker of response to hormonal and cytotoxic agents in advanced and recurrent prostate cancer.
14 PSA decline was studied as a surrogate marker for OS by Petrylak et al. 15 in the SWOG 9916 study. They concluded that a PSA decline of X30% within 3 months after initiation of cytotoxic chemotherapy correlated with OS. In this study, 76% of the patients treated with docetaxel and estramustine achieved this end point, and this was associated with a significant improvement in survival (hazard ratio (HR) ¼ 0.43; 95% confidence interval (CI) 0.34-0.55; Po0.001). 15 Armstrong et al. 16 found that in an independent data set (TAX 327) a PSA decline of X30% within 3 months of starting treatment, despite showing the greatest surrogacy, only accounted for about two-thirds of the OS benefit seen. In this study, 65% of patients met this end point and showed an 8.6-month improvement in median survival over patients not achieving this outcome. 16 Thus, the majority of men achieve this degree of PSA decline, which typically translates into a substantial survival benefit.
Optimal timing for initiation of docetaxel therapy
The current European Association of Urology guidelines for the treatment of CRPC suggest that chemotherapy should be given only after two failures on hormone therapy. 17 Two common reasons for practitioners to initiate chemotherapy are the presence of pain (for palliation) and rapid rises in PSA levels. One question is whether the benefit from chemotherapy differs between men with and without pain at baseline. Cancer-related pain can occur in a migratory pattern, with varying intensity, which makes it difficult for patients to describe to health-care practitioners. However, even subtle pain can result in a poor patient outcome. Data from TAX 327 18 and three Cancer and Leukemia Group (CALGB) multi-institutional Phase III trials 19 of men with CRPC found that those men with higher pain scores at baseline had worse clinical outcomes than those with lower baseline pain scores. The results showed that pain is a significant predictor of OS in men with CRPC and that the presence of pain predicts for a lower degree of PSA decline, tumor response and shorter time to progression.
In TAX 327, 55% of men without significant baseline pain received a median of 27 weeks (mean 21 weeks) of therapy with docetaxel and prednisone, whereas men with significant baseline pain received a median of 21 weeks (mean 17.5 weeks; P ¼ 0.0017 for comparison of means) of therapy (unpublished data). These results illustrate the ability to deliver more chemotherapy over a longer period of time to men without significant baseline pain. Interestingly, the HR for OS associated with 3-weekly docetaxel and prednisone compared with mitoxantrone and prednisone among men without baseline pain was 0.73 (95% CI 0.57-0.93; P ¼ 0.01) compared with 0.85 (95% CI 0.66-1.07; P ¼ 0.19) in those with baseline pain (Figure 2) . 20 This translates into a median survival improvement with docetaxel and prednisone versus mitoxantrone in combination with prednisone of 3.9 months (from 20.0 to 23.9 months) for men without baseline pain and 1.8 months (13.3 to 15.1 months) for those with baseline pain. 4, 13 On the basis of these findings, the use of docetaxel in asymptomatic men and/or those who have minimal pain should strongly be considered to improve survival as well as to delay the onset of cancer-related pain and other symptoms that may interfere with QoL. However, such general recommendations must be balanced on an individual basis against the toxicities of docetaxel-based therapy.
Earlier initiation of chemotherapy in asymptomatic men or men with a lower disease burden may result in a higher degree of clinical benefit in some patients. Prospectively defining a decline in serum PSA level from pretreatment to o4 ng ml À1 (PSA normalization), Armstrong et al. 16 reported significantly longer duration of survival for this subset of patients ( Figure 3 ) compared with all other subsets in TAX 327. Although PSA normalization is a good prognostic marker, it does not meet strict surrogacy criteria for OS, as only 16% of patients treated with docetaxel in TAX 327 achieved this end point. Men who experience PSA normalization are more likely to have PSA-only progression before starting chemotherapy, no visceral metastases and a lower disease burden on bone scan, suggesting that the early use of chemotherapy may potentially offer a greater absolute increase in survival duration. Interestingly, the median time to PSA normalization was 6 months, supporting the continued use of docetaxel. 21 
Prognostic factors and nomograms
Circulating tumor cells (CTCs) may be useful prognostic markers for disease progression and for monitoring tautology response to treatment. They have previously been used to predict outcome and monitor treatment in patients undergoing treatment for metastatic breast cancer. 22 A recent study by Moreno et al. 23 suggested that CTC levels may be a valid surrogate end point for monitoring response to chemotherapy in patients with CRPC. Similarly, several recent studies have found baseline and on-treatment CTC levels to be prognostic for survival, with patients experiencing a reduction in CTC counts showing a survival benefit from systemic chemotherapy. 24, 25 These cells can be evaluated for gene expression patterns, androgen receptor levels, and oncogenic pathways for potential targeted therapy development and have potential to help guide treatment selection. 26, 27 Another biomarker that has potential for predicting response and progression is interleukin-6. George et al. 28 found plasma interleukin-6 levels to have prognostic significance in patients with CRPC from the CALGB 9480 study, supporting the use of interleukin-6 levels in prognostic models.
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Nomograms that combine multiple prognostic variables for progressive disease after radical prostatectomy have been devised by a number of groups 18, 29, 30 to predict survival (Table 2 ). Such nomograms are useful for prognosis and guiding treatment timing, selection and duration, as well as clinical trial design. In addition, these factors can be combined to define risk groups (good/intermediate/poor) based on the number of risk factors present, which can facilitate communication with patients in terms of expected outcomes (PSA declines, survival, tumor response) according to risk category. 31 The prognostic nomograms developed by Halabi et al., 29 Smaltez et al. 30 and Armstrong et al. 18 use clinical information to predict median OS in men with CRPC. The multivariate model designed by Armstrong et al.
18 is based on a single trial (TAX 327) in men receiving the current systemic standard of care. This nomogram was found to have a bootstrap concordance index of 0.69, which compares favorably with the concordance indices seen with the Halabi and Smaltez nomograms, 29, 30 indicating that additional factors are also likely to contribute to OS. These factors could include some of the variables covered in other nomograms, such as lactate dehydrogenase and albumin, as well as factors not captured by these nomograms, such as serum biomarkers for vascular endothelial growth factor 32 and other cytokines, 28 CTCs 23,33 and other unmeasured prognostic factors. 29 Nomograms provide the clinician with an overall assessment of a patient's prognosis, but do not directly impact on decisions for the ideal starting point for docetaxel-based therapy, given that all patients in these nomograms had received therapy. Furthermore, no randomized trials have compared early versus deferred docetaxel in asymptomatic men with CRPC, with or without metastases. Because of this, estimates of the optimal time to start chemotherapy are based on these retrospective subset analyses from the above Phase III trials.
Defining progression: when to stop chemotherapy
The optimal duration for chemotherapy in CRPC has not yet been established. The TAX 327 study 4 used 10 cycles of docetaxel 75 mg m À2 . Nevertheless, it is not uncommon to continue to treat patients until unacceptable toxicity or disease progression. However, it should be noted that there are a number of long-term adverse events associated with continuous docetaxel including asthenia, edema, peripheral neuropathy, nail changes, Figure 2 Survival benefit with docetaxel among various subgroups treated in the TAX 327 study. 13 The left-hand side of the figure describes the subgroups defined in this exploratory analysis, the number of patients in each subgroup, and their median survival time in months, independent of treatment. The right-hand side shows a Forrest plot showing the median hazard ratios and their 95% CIs for survival on the docetaxel arms compared with the mitoxantrone arm. Dz, disease; FACT-P, Functional Assessment of Cancer Therapy-Prostate; KPS, Karnofsky performance status; OS, overall survival. Figure 3 Kaplan-Meier estimates of overall survival according to PSA normalization at any point after random assignment while receiving study chemotherapy in TAX 327. 16 Hazard ratio for overall survival is 0.30 (95% CI, 0.23-0.39) for those men who achieved PSA normalization (n ¼ 115) compared with those who did not (n ¼ 333).
Optimizing docetaxel in metastatic CRPC AJ Armstrong and DJ George tearing and cytopenias (notably neutropenia) that need to be managed. 4, 34 Biomarkers may be good candidates as surrogate end points for clinical trials. A number of prognostic factors including PSA and pain have been investigated as markers for defining progression. 15, 18, 35, 36 The occurrence of PSA 'flares', where there is an initial rise in PSA followed by normalization, must also be noted. Interestingly, 23 patients in the TAX 327 study who displayed an initial PSA increase and fulfilled criteria of progression later had a decline of X50% in serum PSA compared with baseline. It is therefore possible that additional patients may have responded if their treatment had not been stopped or changed soon after randomization. 20 Such results highlight the importance of not discontinuing chemotherapy too early based on PSA progression alone. It is reasonable to administer at least 4 cycles of chemotherapy (that is, continuing for at least 12 weeks) 37 unless there is major clinical deterioration or toxicity. Likewise, pain progression alone may not be a strong indicator of disease progression, as other factors such as compression fractures or noncancer pain in the absence of PSA or radiographic progression may lead to premature discontinuation of therapy. 16 Recent studies have explored the association between OS and progression-free survival, defined on the basis of changes in PSA or radiographic progression in bone and/or soft tissue. 36, 38 Although these measures of progression were highly prognostic for survival, this association was not strong, suggesting that other physiologic processes involving mechanisms imperfectly captured by changes in bone scans or PSA are involved, 38 or that the current definitions used in PSA and bone scan progression do not adequately capture patient benefit and survival outcomes. Composite definitions are likely to be better than individual variables, such as changes in PSA, as individual factors may be dissociated from clinical outcomes. In a multivariate analysis of the TAX 327 data, Armstrong et al. 39 found that continuation of docetaxel and prednisone remained significantly associated with OS beyond progression (HR 0.39, 95% CI 0.27-0.57; Po0.0001) (Figure 4) . However, this benefit was confined primarily to those men with isolated pain progression rather than PSA or tumor progression. The study concluded that the beyond-progression survival advantage observed with continued docetaxel was likely due to the definition of progression used (based on minor pain increases). This highlights the benefit of using composite definitions of progression to reflect the advantage of docetaxel use. 39, 40 Although many different end points have been studied to evaluate response in Phase II and III studies of patients with CRPC, including PSA decline, OS, progression-free survival, pain, QoL, CTCs and Response Evaluation Criteria in Solid Tumors, 41 the only current valid Phase III end point in advanced prostate cancer is OS. Further investigations are required to find an optimal surrogate marker for OS.
The Prostate Cancer Working Group distinguishes two types of objectives for Phase II clinical trials, the first based on controlling, relieving or eliminating disease manifestations present at treatment initiation, and the second based on preventing or delaying future disease manifestations. 37 The Prostate Cancer Working Group suggests expanding the focus of Phase II trials from measures of response to measures of progression/delay due to uncertainties with assessing response in bone and the controversy surrounding the clinical significance of changes in PSA after therapy. 37 End points should reflect the mechanism of action of the agent being studied and should more directly capture patient benefit over time. These changes in definitions of progression will need to be independently validated against OS before their incorporation as primary end points for Phase III studies. Figure 4 Overall survival following pain progression among docetaxel-treated subjects (either schedule) according to continuation of protocol therapy (n ¼ 221). 39 Optimizing docetaxel in metastatic CRPC AJ Armstrong and DJ George
Is weekly docetaxel an acceptable regimen?
Several studies have investigated the efficacy and tolerability of weekly docetaxel. Phase II trials in which docetaxel was used as monotherapy include a study that found a dose of 36 mg m À2 per week to produce a PSA response rate (X50% reduction in PSA) of 41%, time to disease progression and OS of 5.1 and 9.4 months, respectively, and minimal myelosuppression in patients with CRPC. 42 The Oregon Health Studies University study used the same dose with treatment continued until disease progression or unacceptable toxicity. 43 This study found that 48% of patients had at least a two-point reduction in measured pain scales, and of the patients evaluable for biochemical disease response, 46% had a PSA decline of X50%.
However, different conclusions were drawn from the TAX 327 study. Weekly docetaxel (30 mg m À2 with prednisone 5 mg twice daily) was less effective than 3-weekly docetaxel, resulting in 37.4% of 207 men in the weekly arm experiencing a small but significant QoL deterioration, whereas this figure was only 29.1% (of 278 men) in the 3-weekly arm. 20 OS in patients receiving weekly docetaxel was 17.4 months, which was not significantly different from that with mitoxantrone and prednisone. 4 It was therefore suggested that weekly docetaxel should only be used first line in exceptional circumstances, for example, in men with compromised bone marrow reserves who are at high risk of septic neutropenia. In contrast, in second-line use, weekly docetaxel is a well-tolerated and active treatment after mitoxantrone for CRPC, with levels of activity similar to those achieved in the first-line setting. 44 This indicates a possible use for this regimen in the second-line setting.
Second-line chemotherapy should be considered when progression is observed during or after docetaxel treatment. However, there is uncertainty about when to stop first-line chemotherapy and when to initiate secondline therapy. Agents used off-label in the second-line setting include mitotic spindle agents (vinorelbine, estramustine, others), etoposide, cyclophosphamide, mitoxantrone, and these therapies have been reviewed extensively elsewhere. Referral for clinical trials remains a priority in this second-line setting, given the lack of a proven standard (http://clinicaltrials.gov/ct2/show/ NCT00417079).
Is there a benefit to chemotherapy holidays and re-treatment with docetaxel?
Breaks in treatment schedules for patients who experience an initial response to chemotherapy may avoid or delay the development of progressive toxicity that can occur with continuous chemotherapy. In addition, the 'off-chemotherapy' periods offer a window of opportunity to evaluate less toxic biologic and other investigational agents for their potential in prolonging progression-free survival and OS.
There is currently no evidence to suggest differences in OS for continuous versus intermittent treatments in prostate cancer, although this could be due to inadequate power to detect survival differences in the studies conducted so far. 34 To determine the relative merits of one approach over the other, it is important to assess QoL during the periods on and off chemotherapy. For example, there may be no difference in OS when comparing continuous and intermittent schedules, but deterioration in QoL with one of these approaches may aid in treatment selection.
Currently no data are available from randomized Phase III trials comparing intermittent versus continuous chemotherapy in CRPC. Although three single-arm trials of intermittent chemotherapy for CRPC have yielded interesting results, it remains a challenge to assess these data in the context of current treatment practices due to patient selection biases, lack of control arms and the use of nonstandard chemotherapy regimens or schedules consisting of weekly docetaxel. [45] [46] [47] Furthermore, intermittent chemotherapy was optional in two of these studies in which patients self-selected treatment. None of the three studies investigated maintenance biologic therapy in the periods off chemotherapy.
A multicenter, two-arm, randomized Phase II trial in chemotherapy-naive patients with CRPC that uses 3-weekly docetaxel and prednisone is ongoing (http:// clinicaltrials.gov/ct2/show/NCT00488982). This study compares nonchemotherapeutic (maintenance) therapy in the form of granulocyte-macrophage colony-stimulating factor or placebo given during the observation periods of an intermittent chemotherapy schedule. Granulocyte-macrophage colony-stimulating factor has shown single-agent activity both in patients with CRPC 48, 49 and in those with serological progression only, 50 thus making it a reasonable choice as a maintenance agent between chemotherapy treatments. The results of this multicenter trial should provide some insight into whether QoL can be improved in patients who are not subjected to continuous chemotherapy.
Future directions
The benefits of the early use of chemotherapy in CRPC remain undefined. However, a number of studies using neoadjuvant chemotherapy have been initiated. The TAX 3503 study (http://clinicaltrials.gov/show/NCT00514917) aims to evaluate and compare the efficacy of ADT with or without docetaxel in clinically asymptomatic patients with non-metastatic prostate cancer and rising PSA after radical prostatectomy. Efficacy is being assessed in this by comparing the median progression-free survival during 18 months of therapy and at least 18 months of follow-up. Another similar study is the neoadjuvant CALGB 90203 randomized Phase III trial (http://clinicaltrials.gov/ct2/ show/NCT00430183) studying docetaxel and leuprolide or goserelin when given before radical prostatectomy compared with surgery alone in treating patients with high-risk localized prostate cancer. A third study, Radiation Therapy Oncology Group 0521 (http://clinicaltrials. gov/ct2/show/NCT00288080) compares hormone therapy and radiation therapy with or without docetaxel and prednisone in the adjuvant setting. Successful accrual to these studies will require multidisciplinary collaboration and completion may shed some light on the benefits of early use of chemotherapy.
Optimizing docetaxel in metastatic CRPC AJ Armstrong and DJ George A number of trials have been conducted to investigate the value of vaccines in maintenance therapy for prostate cancer. Two recent Phase III trials (VITAL-1 and VITAL-2) (http://clinicaltrials.gov/ct2/show/NCT00089856; http://clinicaltrials.gov/ct2/show/NCT00133224) of the granulocyte-macrophage colony-stimulating factor genetransduced allogeneic prostate cancer vaccine (GVAX) were both terminated early. VITAL-1 was designed to compare GVAX monotherapy with docetaxel and prednisone in patients with metastatic CRPC who were asymptomatic. The trial was terminated based on a futility analysis by the Independent Data Monitoring Committee, showing the chance of the trial meeting its predefined primary end point of an improvement in survival to be o30%. VITAL-2 was designed to compare GVAX in combination with docetaxel against docetaxel and prednisone in patients with metastatic HRPC who were symptomatic with respect to cancer-related pain. This trial was terminated by the Independent Data Monitoring Committee after a routine safety review meeting that observed a higher mortality in the GVAX arm than in the chemotherapy arm. One prostate cancer vaccine trial has recently reported positive Phase III results. In this study, sipuleucel-T, an autologous prostatic acid phosphatase/granulocyte-macrophage colony-stimulating factor antigen-presenting cell vaccine, showed improved OS without a noticeable alteration in progression rates in men with relatively asymptomatic metastatic CRPC. 51 These data highlight the need for an improved understanding of measures of progression and response in this disease, particularly in the context of novel targeted or immunotherapy agents.
Conclusions
The publication of two landmark studies-TAX 327 4 and SWOG 9916, 5 both of which showed a survival benefit with docetaxel-has led to evolution in the management of CRPC. The survival benefit associated with the administration of chemotherapy to patients with CRPC is now well established. 4, 5, 13 These studies have also resulted in a radical change in the treatment algorithm for prostate cancer; a closer partnership between a multidisciplinary team consisting of urologists, radiation oncologists and medical oncologists; and a drive to explore the potential benefits of introducing chemotherapy at earlier stages of the disease.
Three-weekly docetaxel and prednisone has become the standard first-line chemotherapy in men with CRPC; however, there is currently no clear guideline as to when chemotherapy should be initiated. The use of prognostic models for assessing patient prognosis 18 may aid decisions on the timing and duration of chemotherapy by combining a number of relevant variables. Treatment decisions for patients with CRPC are very complex, from the timing of initiation through to deciding when to discontinue chemotherapy on progression. Initiating first-line chemotherapy before the onset of bone pain in these patients may result in greater benefits in terms of OS. There is currently no clear surrogate for disease progression or OS in CRPC and no standard second-or third-line therapy after progression on first-line therapy. Although treatment within a clinical trial is necessary to improve treatment for men with CRPC, many men are not enrolled in trials for a variety of reasons, and thus optimizing treatment outside the clinical trial setting is essential for improving patient outcomes.
